TCRX — Tscan Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.21m
- -$54.17m
- $10.33m
Brief: Tscan Therapeutics Announces Updates To Its Board Of Directors
Brief: Tscan Therapeutics Receives FDA’S Regenerative Medicine Advanced Therapy (Rmat) Designation For Its Two Lead Tcr-T Therapy Candidates For The Treatment Of Heme Malignancies
TScan Therapeutics rises after upsized $150 mln stock offering
Brief: Tscan Therapeutics Announces Pricing Of Upsized $150 Mln Public Offering
Brief: TScan Therapeutics Announces Launch Of $125 Million Proposed Public Offering
Brief: TScan Therapeutics Provides Clinical Pipeline Update And Highlights Near-Term Priorities
Brief: TScan Therapeutics Q4 Net Income USD -19.613 Million
Brief: TScan Therapeutics Appoints Industry Executive Jason Amello As CFO
Brief: TScan Therapeutics Announces 2024 Clinical Plans
Brief: Tscan Therapeutics Presents Initial Phase 1 Clinical Results On Tsc-100 And Tsc-101
Brief: TScan Therapeutics Reports Third Quarter 2023 Financial Results And Provides Corporate Update
Brief: TScan Therapeutics, Inc. Q2 basic EPS USD -0.51
Brief: TScan Therapeutics Inc Says On July 20 Appointed Gavin Macbeath As Interim Principal Financial Officer Of Co, Effective July 21
Brief: Adage Capital Partners Reports 9.35% Passive Stake In TScan Therapeutics
U.S. STOCKS ON THE MOVE-Cenovus Energy, Compass Pathways,
U.S. STOCKS ON THE MOVE-NovoCure, Intuit, Splash Beverage
U.S. STOCKS ON THE MOVE-TScan Therapeutics, Palantir, Coinbase Global
TScan Therapeutics rises on FDA nod to begin human study for cancer therapy
Brief: TScan Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TSC-200-A0201